Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Nat Commun ; 6: 6175, 2015 Jan 28.
Article in English | MEDLINE | ID: mdl-25629724

ABSTRACT

Pancreatic ductal adenocarcinoma (PDAC) has a grim prognosis with <5% survivors after 5 years. High expression levels of ADAM8, a metalloprotease disintegrin, are correlated with poor clinical outcome. We show that ADAM8 expression is associated with increased migration and invasiveness of PDAC cells caused by activation of ERK1/2 and higher MMP activities. For biological function, ADAM8 requires multimerization and associates with ß1 integrin on the cell surface. A peptidomimetic ADAM8 inhibitor, BK-1361, designed by structural modelling of the disintegrin domain, prevents ADAM8 multimerization. In PDAC cells, BK-1361 affects ADAM8 function leading to reduced invasiveness, and less ERK1/2 and MMP activation. BK-1361 application in mice decreased tumour burden and metastasis of implanted pancreatic tumour cells and provides improved metrics of clinical symptoms and survival in a Kras(G12D)-driven mouse model of PDAC. Thus, our data integrate ADAM8 in pancreatic cancer signalling and validate ADAM8 as a target for PDAC therapy.


Subject(s)
ADAM Proteins/metabolism , Membrane Proteins/metabolism , Molecular Targeted Therapy , Pancreatic Neoplasms/drug therapy , ADAM Proteins/antagonists & inhibitors , Animals , Blotting, Western , Carcinoma, Pancreatic Ductal/enzymology , Carcinoma, Pancreatic Ductal/pathology , Cell Line, Tumor , Cell Movement/drug effects , Extracellular Space/metabolism , Focal Adhesion Protein-Tyrosine Kinases/metabolism , Gene Knockdown Techniques , Humans , Hydroxamic Acids/pharmacology , Hydroxamic Acids/therapeutic use , Integrin beta1/metabolism , Kaplan-Meier Estimate , Matrix Metalloproteinase 14/metabolism , Matrix Metalloproteinase 2/metabolism , Membrane Proteins/antagonists & inhibitors , Mice , Neoplasm Invasiveness , Pancreatic Neoplasms/enzymology , Pancreatic Neoplasms/pathology , Peptides, Cyclic/pharmacology , Peptides, Cyclic/therapeutic use , Phosphorylation/drug effects , Protein Binding/drug effects , Protein Multimerization/drug effects , Protein Processing, Post-Translational , Signal Transduction/drug effects
2.
J Immunol ; 190(7): 3798-805, 2013 Apr 01.
Article in English | MEDLINE | ID: mdl-23447685

ABSTRACT

Alternatively activated macrophages express the pattern recognition receptor scavenger receptor A (SR-A). We demonstrated previously that coculture of macrophages with tumor cells upregulates macrophage SR-A expression. We show in this study that macrophage SR-A deficiency inhibits tumor cell migration in a coculture assay. We further demonstrate that coculture of tumor-associated macrophages and tumor cells induces secretion of factors that are recognized by SR-A on tumor-associated macrophages. We tentatively identified several potential ligands for the SR-A receptor in tumor cell-macrophage cocultures by mass spectrometry. Competing with the coculture-induced ligand in our invasion assay recapitulates SR-A deficiency and leads to similar inhibition of tumor cell invasion. In line with our in vitro findings, tumor progression and metastasis are inhibited in SR-A(-/-) mice in two in vivo models of ovarian and pancreatic cancer. Finally, treatment of tumor-bearing mice with 4F, a small peptide SR-A ligand able to compete with physiological SR-A ligands in vitro, recapitulates the inhibition of tumor progression and metastasis observed in SR-A(-/-) mice. Our observations suggest that SR-A may be a potential drug target in the prevention of metastatic cancer progression.


Subject(s)
Macrophages/metabolism , Ovarian Neoplasms/genetics , Pancreatic Neoplasms/genetics , Scavenger Receptors, Class A/genetics , Animals , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/pharmacology , Cell Line, Tumor , Coculture Techniques , Disease Models, Animal , Disease Progression , Female , Gene Expression Regulation, Neoplastic , Humans , Ligands , Lung Neoplasms/genetics , Lung Neoplasms/secondary , Mice , Mice, Knockout , Neoplasm Invasiveness/genetics , Ovarian Neoplasms/drug therapy , Ovarian Neoplasms/metabolism , Ovarian Neoplasms/pathology , Pancreatic Neoplasms/drug therapy , Pancreatic Neoplasms/metabolism , Pancreatic Neoplasms/pathology , Polyelectrolytes , Polymers/metabolism , Protein Binding , Scavenger Receptors, Class A/antagonists & inhibitors , Scavenger Receptors, Class A/deficiency , Scavenger Receptors, Class A/metabolism , Tumor Burden/drug effects
3.
J Clin Invest ; 121(12): 4685-99, 2011 Dec.
Article in English | MEDLINE | ID: mdl-22056382

ABSTRACT

The majority of human pancreatic cancers have activating mutations in the KRAS proto-oncogene. These mutations result in increased activity of the NF-κB pathway and the subsequent constitutive production of proinflammatory cytokines. Here, we show that inhibitor of κB kinase 2 (Ikk2), a component of the canonical NF-κB signaling pathway, synergizes with basal Notch signaling to upregulate transcription of primary Notch target genes, resulting in suppression of antiinflammatory protein expression and promotion of pancreatic carcinogenesis in mice. We found that in the Kras(G12D)Pdx1-cre mouse model of pancreatic cancer, genetic deletion of Ikk2 in initiated pre-malignant epithelial cells substantially delayed pancreatic oncogenesis and resulted in downregulation of the classical Notch target genes Hes1 and Hey1. Tnf-α stimulated canonical NF-κB signaling and, in collaboration with basal Notch signals, induced optimal expression of Notch targets. Mechanistically, Tnf-α stimulation resulted in phosphorylation of histone H3 at the Hes1 promoter, and this signal was lost with Ikk2 deletion. Hes1 suppresses expression of Pparg, which encodes the antiinflammatory nuclear receptor Pparγ. Thus, crosstalk between Tnf-α/Ikk2 and Notch sustains the intrinsic inflammatory profile of transformed cells. These findings reveal what we believe to be a novel interaction between oncogenic inflammation and a major cell fate pathway and show how these pathways can cooperate to promote cancer progression.


Subject(s)
Basic Helix-Loop-Helix Transcription Factors/physiology , Carcinoma, Pancreatic Ductal/pathology , Gene Expression Regulation, Neoplastic , Homeodomain Proteins/physiology , I-kappa B Kinase/physiology , NF-kappa B/physiology , Neoplasm Proteins/physiology , PPAR gamma/antagonists & inhibitors , Pancreatic Neoplasms/pathology , Receptors, Notch/physiology , Signal Transduction/physiology , Tumor Necrosis Factor-alpha/physiology , Animals , Carcinoma, Pancreatic Ductal/genetics , Carcinoma, Pancreatic Ductal/metabolism , Carcinoma, Pancreatic Ductal/prevention & control , Disease Progression , Down-Regulation , Genes, ras , Histones/metabolism , I-kappa B Kinase/antagonists & inhibitors , I-kappa B Kinase/genetics , Inflammation , Mice , Mice, Inbred C57BL , Neoplasm Proteins/biosynthesis , Neoplasm Proteins/genetics , PPAR gamma/agonists , PPAR gamma/biosynthesis , PPAR gamma/genetics , Pancreatic Diseases/genetics , Pancreatic Diseases/pathology , Pancreatic Neoplasms/genetics , Pancreatic Neoplasms/metabolism , Pancreatic Neoplasms/prevention & control , Phosphorylation , Precancerous Conditions/genetics , Precancerous Conditions/pathology , Protein Processing, Post-Translational , Proto-Oncogene Mas , RNA, Small Interfering/pharmacology , Rosiglitazone , Signal Transduction/drug effects , Thiazolidinediones/pharmacology , Thiazolidinediones/therapeutic use , Transcription Factor HES-1 , Tumor Necrosis Factor-alpha/genetics , Tumor Necrosis Factor-alpha/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...